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Liver fat was associated not only with enhanced hepatic glucose production, but 
also with skeletal muscle insulin resistance, supporting a central role of fatty liver in 
systemic insulin resistance and existence of a network between the liver and skeletal 
muscle. Palmitate and cholesterol act as toxic lipids to cause hepatic insulin resistance via 
mitochondria-derived oxidative stress. Obesity mediated disruption in crosstalk among 
protein-, glucose- and lipid-metabolism pathways results in hepatic insulin resistance, 
enhanced gluconeogenesis and liver steatosis by impairing proteasome function. The 
liver plays as an endocrine organ to produce functional hepatokines and thereby mediates 
fatty liver-associated skeletal muscle insulin resistance through unique mechanisms. 
Selenoprotein P is upregulated through FoxOs and hyperglycemia, and causes resistance 
to insulin, angiogenesis and exericise through reductive stress. LECT2 is upregulated in 
satiety through AMPK inactivation, and contributes to the development of muscle insulin 
resistance and obesity by activating JNK and by impairing myogenesis, respectively.  
Therefore, overnutrition evokes remodeling of nutrient homeostasis by toxic 
lipids and proteasome dysfunction in the liver. The remodeling also results in 
overproduction of hepatokines that disrupt inter-organ network leading to pathology of 
diabetes.  
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Insulin resistance is a core pathology of type 2 diabetes mellitus, nonalcoholic 
fatty liver disease (NAFLD), and cardiovascular diseases. The severity of insulin 
resistance may differ among the major insulin-target organs, the liver, skeletal muscle, 
and adipose tissue, suggesting that these organs cross-talk each other to keep whole body 
energy homeostasis. Disruption of inter-organ networks leads to insulin resistance. 
Over-nutrition is one of the major environmental factors that disrupt the inter-organ 
networks (1). Although obesity is less common (2), diabetes is a huge and growing 
problem in Asia (3), suggesting that Asian people may be feasible to obesity-associated 
metabolic dysregulation. Accumulating evidence suggests that ectopic fat accumulation 
in insulin-target organs leads to development of insulin resistance in each organ by 
altering oxidative stress (4, 5) and gene expression profiles (6, 7). Specifically, the liver 
functions as a center to maintain whole body energy homeostasis by sensing nutrient 
stimuli and by producing a variety of nutrients and bioactive substances.  
In this review, we show the clinical evidence for significance of liver fat in whole 
body glucose homeostasis, remodeling of nutrient homeostasis in the liver, and interorgan 
networks via liver-derived hormone hepatokines.   
 
14.2 Ectopic fat accumulation and organ-specific insulin resistance 
Disruption of hepatic insulin signaling in liver-speciﬁc insulin receptor knockout 
(LIRKO) mice results in fasting and postprandial hyperglycemia and the subsequent 
development of peripheral (muscle) insulin resistance (8), whereas glucose homeostasis 
remains normal in mice of disrupted insulin signaling both in the skeletal muscle and 
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adipose tissue (9). These observations suggest that hepatic insulin resistance is the 
primary event leading to diabetes and the subsequent development of peripheral tissue 
insulin resistance. Indeed, liver steatosis is associated with whole-body insulin resistance, 
independently of body mass index (BMI), in Japanese patients with NAFLD (10). 
However, the role of intramyocellular fat accumulation in insulin sensitivity is also on 
debate, and no previous studies have demonstrated the association among the insulin 
targeting organs comprehensively and simultaneously. Therefore, to understand organ 
networks that sense excessive energy and regulate insulin action, elucidating the 
association between fat accumulation and organ-specific insulin resistance among the 
liver, skeletal muscle, and adipose tissue is important, especially in humans.  
We have addressed the association of ectopic fat accumulation with 
organ-specific insulin resistance among the liver, skeletal muscle, and adipose tissue in 
Japanese patients with NAFLD, systematically using reliable methods including liver 
biopsy, assessment of glucose metabolism measured by an euglycemic hyperinsulinemic 
clamp study with stable-isotope, bioelectrical impedance analysis, and proton magnetic 
resonance spectroscopy (1H-MRS) (11). As shown in Table 1, both histological iver 
steatosis score and intrahepatic lipid (IHL) are significantly correlated negatively with a 
muscle insulin sensitivity index Rd and positively with a hepatic insulin resistance index 
HGP × fasting plasma insulin (FPI) (Table 1). In the multiple regression analysis, liver 
steatosis score is significantly correlated with both HGP × FPI (β = 0.284, P <0.05) and 
Rd (β = -0.300, P <0.01) after adjusted with age, sex, and BMI. Unexpectedly, 
intramyocellular lipid (IMCL) is associated neither with their own organ-specific insulin 
resistance nor any of organ-specific insulin resistance index (Table 1). Adipose tissue 
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mass is correlated with HGP × FPI and Rd, but not with % suppression of free fatty acids, 
an adipose tissue insulin sensitivity index (Table 1) (11). Therefore, indices of fat 
accumulation in the skeletal muscle and adipose tissue are not associated with their own 
organ-specific insulin resistance (Figure 1). It is known that IMCL is increased not only 
with obesity but also by enhanced physical fitness (12). Therefore, absolute fat contents 
do not always predict insulin resistance in the skeletal muscle. Rather, toxic lipids that 
cause insulin resistance in the skeletal muscle should be further researched. On the other 
hand, hepatic steatosis per se is central surrogate pathology indicative of insulin 
resistance in both liver and skeletal muscle in patients with NAFLD (Figure 1). There 
may be a network between the liver and skeletal muscle to maintain whole body energy 
homeostasis (Figure 1). To date, whether hepatic steatosis is a consequence or cause of 
skeletal muscle insulin resistance remains uncertain because a longitudinal observation of 
the relationship is lacking. However, some possibilities are assumed for the link as 
follows:  1) Skeletal muscle insulin resistance causes obesity and subsequent hepatic 
steatosis as experimentally shown in mice with muscle-selective insulin resistance (13). 
Indeed, Flannery et al. recently reported that skeletal muscle insulin resistance promotes 
increased hepatic de novo lipogenesis and hepatic steatosis in the elderly (14). 2) The 
neuronal pathway from the liver might modulate peripheral insulin sensitivity (15). 3) 
Some nutrients, such as fatty acids and amino acids, might link hepatic steatosis and 
skeletal muscle insulin resistance (16). 4) A liver-derived hormone named as  hepatokine 
affects the distant organ insulin sensitivity (17). Molecular mechanisms underlying the 






14.3 Possible molecular mechanisms underlying mystery of the selective insulin 
resistance in the type 2 diabetic liver 
In the liver, insulin suppresses glucose production and enhances lipogenesis. 
Indeed, total insulin resistance in the liver observed in the LIRKO mice present 
hyperglycemia without fatty liver (8). However, in the liver with type 2 diabetes, insulin 
fails to suppress gluconeogenesis but still activates lipogenesis, the pathology of which is 
regarded as a ‘selective insulin resistance’-like phonotype (18) (Figure 2). Notably, the 
indices for hepatic fat accumulation are associated with HGP × FPI, but not with % 
suppression of HGP during the hyperinsulinemic clamp (Table 1) (11), suggesting that 
the liver fat is associated with basal HGP itself, possibly independently of insulin 
resistance. Indeed, HGP is not solely regulated by insulin, but also by other hormones 
such as glucagon and glucocorticoid. Transcription factors such as forkhead box protein 
O (FoxO), cAMP response element-binding protein (CREB), peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), hepatocyte nuclear 
factor 4 (HNF4α), and glucocorticoid receptors are involved in regulation of 
gluconeogenesis by the hormones and nutrients. In addition, hepatic steatosis also occurs 
independently of insulin resistance. Of the triacylglycerol accumulated in the liver of 
patients with NAFLD, 59.0% arises from non-esterified fatty acids mainly derived from 
the adipose tissue and 14.9% from the diet, whereas only 26.1% from de novo lipogenesis 
(19). Transcription factors such as liver X receptor (LXR), sterol regulatory 
element-binding protein-1c (SREBP-1c), and carbohydrate response element binding 
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protein (ChREBP) are involved in the de novo lipogenesis. Of these, SREBP-1c is a 
master regulater of hepatic de novo synthesis of fatty acids and is activated not only by 
insulin, but also by glucose, fatty acids, amino acids, SREBP-1c itself, LXR, mechanistic 
target of rapamycin complex 1 (mTORC1) and endoplasmic reticulum (ER) stress (20).  
Triglyceride itself is not a toxic lipid and rather may be protective to prevent toxic 
effects of free fatty acids. Rather, free cholesterol and saturated free fatty acid palmitate 
are regarded as toxic lipids that cause hepatic insulin resistance via oxidative stress (17)as 
follows:  
1) Mice fed an atherogenic diet rich in cholesterol and cholate show 
steatohepatitis, oxidative stress, and hepatic insulin resistance (4). In the liver of this 
model, SREBP-1c is upregulated possibly via cholesterol-mediated LXR activation, 
suggesting de novo lipogenesis in the liver. In addition, hepatic expression of insulin 
receptor substrate (IRS)-2 was downregulated by cholesterol diet. Shimano et al. 
discovered that SREBP-1c binds to E-box in the promoter of IRS-2 competitively with 
TFE3 and FoxO1, and thus down-regulates IRS-2 (21). These findings may link 
lipogenesis and insulin resistance in the liver.  
2) In an in vitro fatty liver system using H4IIEC3 hepatocytes, a saturated fatty 
acid palmitate, but not an unsaturated fatty acid oleate, inhibits insulin-stimulated 
tyrosine phosphorylation of insulin receptor substrate 2 and serine phosphorylation of 
Akt, through c-Jun NH2-terminal kinase (JNK) activation (5). In this model, 
mitochondrial β oxidation-derived reactive oxygen species (ROS) play a causal role in 
the palmitate-induced JNK activation (5). Therefore, toxic lipid-induced mitochondrial 
ROS may also underlie the link between steatosis and insulin resistance in the liver. 
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Indeed, in human, genes involved in mitochondrial oxidative phosphorylation 
(OXPHOS) are coordinately upregulated and positively correlated with those involved in 
a ROS-related pathway in the livers of obese type 2 diabetic patients compared with those 
of non-obese type 2 diabetic patients (7). These findings in toxic lipids-induced hepatic 
steatosis also contribute to the selective insulin resistance-like phonotype in type 2 
diabetic livers (18). 
 
14.4 Cross-talk among glucose, protein and lipid metabolic pathways in the liver 
Growing evidence suggests that chronic endoplasmic reticulum (ER) stress in the 
liver is a major contributor to obesity-induced insulin resistance (22, 23). ER is 
responsible for protein quality control (24). The burden of unfolded proteins in the ER 
lumen is identified as an ER stress by several ER stress sensors, known as ATF6, PERK 
and IRE-1. The ER stress sensors trigger cellular adaptation for unfolded protein 
accumulation to restore normal function of the cell, which is called as the unfolded 
protein response (UPR). Chronic UPRs are causally linked to the pathogenesis of human 
metabolic diseases such as obesity and type 2 diabetes. Accumulating evidence suggests 
that obesity promotes ER stress, which is detected as an enhanced UPR signaling, that 
activates c-jun N terminal kinase (JNK) and impairs insulin signaling at the level of IRSs 
in the liver and adipose tissue (25). However, the molecular mechanisms linking obesity 
and ER stress are not fully understood. 
In searching for metabolic pathways that are significantly altered by obesity in the 
livers of people with type 2 diabetes, we found that genes involved in 
ubiquitin-proteasome pathways are coordinately upregulated in obese individuals (7). 
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Proteasomes play fundamental roles in processes that are essential for cell viability by 
degrading misfolded proteins (26). Unexpectedly from the expression data, liver 
proteasome activity was reduced by approximately 30-40% in mouse models of obesity, 
such as genetically obese ob/ob mice, diabetic db/db mice, and C57BL/6 mice fed a high 
fat diet (HFD) (27). As a consequence, ubiquitinated proteins were accumulated in the 
liver of these obese model mice. These results suggest that liver proteasome activity is 
reduced in animal models of obesity. Thus, coordinate upregulation of the genes involved 
in the ubiquitin-proteasome pathway in obese patients and mouse models of obesity may 
compensate for impaired proteasome function. Therefore, we hypothesized that 
proteasome dysregulation in the liver is involved in the development of hepatic insulin 
resistance in obesity and type 2 diabetes. To test this hypothesis, we generated 
PA28α-PA28β-PA28γ triple-knockout (PA28 KO) mice, the genes of which are 
up-regulated in the livers of patients with obesity and in those of mice fed HFD (27), as a 
model of impaired proteasome function and investigated their metabolic phenotypes as 
follows:  1) Hepatic proteasome activity in PA28 KO mice fed a standard chow was 
reduced by 35% as compared with wild-type mice. As expected, ubiquitinated proteins 
were accumulated in the liver of the PA28 KO mice. 2) Electron micrographs revealed 
massive expansion of the ER in the livers of PA28 KO mice, suggestive of an unfolded 
protein response (UPR). Indeed, the liver in PA28 A28 KO mice showed the evidence of 
ER stress, such as increased levels of Grp78, CHOP, p-PERK, p-eIF2α, and p-IRE-1α, as 
well as ER stress-inducible mRNAs encoding CHOP and the spliced form of XBP-1 
(XBP-1s), as compared with wild-type mice. 3) Phosphorylation of JNK and its 
downstream target c-Jun were significantly increased in the livers of PA28 KO mice as 
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compared with those of wild-type mice. 4) Although body weight was not altered, PA28 
KO mice fed the standard chow presented glucose intolerance. 
Hyperinsulinemic-euglycemic clamp experiments and western blot analysis of the insulin 
signaling pathway revealed that PA28 deficiency impairs insulin signaling mainly in the 
liver, but not in the skeletal muscle, and thereby induces systemic glucose intolerance in 
vivo. These findings illustrate that proteasome dysfunction causes ER stress, JNK 
activation, and thereby cause insulin resistance in the liver (Figure 3). Yang et al. reported 
that hepatic autophagy is downregulated in the livers of ob/ob mice and that defective 
autophagy in Atg7 KO mice causes ER stress and hepatic insulin resistance (28). 
Therefore, it is possible that both proteasome- and autophagy-mediated protein 
degradation are impaired in the livers of obese individuals, further exacerbating ER 
stress.  
5) PA28 KO mice showed hepatic steatosis associated with upregulated Srebf1 and 
Acc1, and increased cleaved/active SREBP-1c (Figure 3). SREBP-1c is activated by ER 
stress (20). In addition, proteasome dysfunction results in increased protein levels of 
SREBP-1c because proteasome is responsible for degradation of SREBP-1c (29).  
6) FoxO1 protein amounts dramatically increased in both cytoplasmic and nuclear 
fractions, probably due to proteasome dysfunction in the liver of PA28 KO mice (Figure 
3). Spliced XBP-1 directly binds FoxO1 and promotes its protein degradation via the 
proteasome (30). In the liver of PA28 KO mice, spliced XBP1 protein was increased, 
probably due to increased phosphorylation of IRE1α, an endonuclease for XBP1 gene. In 
addition, hepatic insulin resistance caused by ER stress/JNK pathway and increased 
SREBP-1c that downregulates IRS-2 further accumulates FoxO1 in the nucleus, leading 
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to induction of genes involved in gluconeogenesis such as Pepck1.  
These findings suggest that proteasome dysfunction may be a primary event linking 
obesity and ER stress-induced insulin resistance in the liver. In addition, there seems to be 
a crosstalk among protein-, glucose- and lipid-metabolism pathways (Figure 3). Notably, 
activation of SREBP-1c and FoxO1 occurred independently of insulin resistance, and 
may mimic so-called ‘selective insulin resistance’ in the liver with type 2 diabetes, that is, 
coexistence of fatty liver and enhanced gluconeogenesis (Figure 2).  
Proteasome function seems to be altered differently in different tissues. 
Insulinopenic hyperglycemia impairs proteasome activity in the liver and kidney (31, 32), 
whereas proteasome activity is enhanced in the wasted muscle of obese diabetic db/db 
mice (33). Taken together, these results indicate that obesity predominantly induces 
proteasome dysfunction in the liver. This clarifies the previous finding that ER stress 
causes insulin resistance in the liver together with the adipose tissue (22) and brain (34). 
Significance of enhanced proteasome activity in the skeletal muscle of obese model mice 
should be investigated in future.  
 
14.5 Role of hepatokines that mediate inter-organ network during remodeling 
of energy homeostasis 
As described above, we hypothesized that a liver-derived hormone, hepatokine, 
affects the distant organ insulin sensitivity. Human hepatic gene expression information 
accmulated by using serial analysis of gene expression (SAGE) technique and DNA chip 
methods (35, 36) were used to identify genes with signal peptides whose hepatic 
expression levels were significantly correlated with glycemic control (HbA1c), obesity 
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(BMI), or insulin resistance (HOMA-R and metabolic clearance rate). Expression of the 
candidates hepatokine genes were further referred to the various animal models of 
diabetes, obesity and fatty liver (4, 37-39). Based on these approaches, we isolated 62 
candidate genes for hepatokines associated with insulin resistance, hyperglycemia, and 
obesity (35).  
 
14.5.1 Selenoprotein P 
Of these, we identified a gene encoding selenoprotein P, the expression levels of 
which were positively correlated with insulin resistance and hyperglycemia (40). Indeed, 
serum levels of selenoprotein P are elevated in people with type 2 diabetes, and 
significantly correlated with fasting plasma glucose and HbA1c levels (40). 
Selenoprotein P (in humans encoded by the SEPP1 gene) is upregulated through FoxOs 
(Figure 4). Insulin downregulates SEPP1 by phosphorylating and inactivating FoxO1 
(41), whereas antidiabetic metformin activates AMPK, phosphorylates and inactivates 
FoxO3a, and thereby downregulates SEPP1 in hepatocytes (42).  
Selenoprotein P causes insulin resistance in the liver at least in part by inactivating 
AMP-activated protein kinase (AMPK) (40) (Figure 4). Selenoproein P also impairs 
angiogenesis by inducing VEGF resistance in vascular endothelial cells (43).  
Specifically, selenoprotein P acts as a redox protein by activating glutathione 
peroxidase. Unexpectedly in the large-scale intervention study, selenium 
supplementation was paradoxically associated with an increased risk for diabetes in 
humans (44). Also, in our previous study in a cultured hepatocyte cell line, anti-oxidant 
reagents, N-acetyl-L-cysteine, rescued palmitate-induced insulin resistance only partly, 
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whereas it effectively suppressed palmitate-induced activation of JNK (5). To solve this 
paradox, we addressed the concentration-dependent effects of ROS on insulin signaling 
in hepatocytes. Treatment with high concentrations of H2O2 reduced insulin-stimulated 
Akt phosphorylation by activating JNK, whereas lower concentrations of H2O2 enhanced 
insulin-stimulated phosphorylation of Akt by suppressing PTP1B activity (45). Therefore, 
depending on its concentration, H2O2 can have the positive or negative effect on insulin 
signal transduction in hepatocytes. It might be possible that selenoprotein P deprives a 
physiologic ROS burst that is required for insulin signal transduction and thereby causes 
insulin resistance, the condition referred to a reductive stress. Indeed, similar to the 
selenoprotein P KO mice, mice lacking one of the selenoproteins involved in the 
elimination of physiological ROS, glutathione peroxidase 1, are reported to be protected 
from high-fat-diet-induced insulin resistance (46).  
Interestingly, supplementation with antioxidants may preclude health-promoting 
effects of physical exercise in humans (47). Consistent with the concept of mitohormesis, 
exercise-induced oxidative stress ameliorates insulin resistance and causes an adaptive 
response promoting endogenous antioxidant defense capacity. In this regard, we recently 
identified a putative skeletal muscle receptor for selenoprotein P. Molecular mechanisms 
how selenoprotein P causes skeletal muscle insulin resistance are under investigation 
through investigating the skeletal muscle-specific selenoprotein P KO mice (Figure 4).  
Serum levels of selenoprotein P are inversely associated with serum levels of 
adiponectin (48) that enhance skeletal muscle insulin sensitivity (49). Therefore, 
overproduction of selenoprotein P in association with hepatic steatosis, by directly or 





Our second hepatokine is leukocyte cell-derived chemotaxin 2 (LECT2), the gene 
of which is most correlated with BMI (50). LECT2 is a 16 kDa secretory protein 
originally identified from cultured supernatant of human T-cell line as a neutrophil 
chemotactic factor (51). LECT2 (in humans encoded by the LECT2 gene) is expressed 
preferentially by human adult and fetal liver cells and is secreted into the blood stream 
(52). LECT2 enhances macrophage function via the CD209a/DC-SIGN receptor and 
improves immunity in bacterial sepsis (53). More recently, it has been reported that 
LECT2 suppresses hepatocellular carcinoma by direct binding and inactivating 
hepatocyte growth factor (HGF) receptor MET (54). However, the role of LECT2 in the 
development of obesity and insulin resistance was unknown. We characterized molecular 
aspects of LECT2 as follows:  1) Serum Lect2 levels were correlated positively with BMI, 
waist circumference, HOMA-R, and HbA1c, and negatively with insulin sensitivity 
Matsuda index (50). These data indicate that the serum levels of LECT2 are positively 
associated with both adiposity and the severity of insulin resistance in humans. 2) Lect2 
was up-reguleted in HFD (vs. standard chow) feeding, fed (vs. fasted) state, and resting 
(vs. exercise) state. In these experimental conditions, AMPK phosphorylation was 
impaired. Indeed, Lect2 expression in H4 hepatocytes was upregulated by dominant 
negative-AMPK infection, whereas downregulated by constitutive active-AMPK 
transfection. These findings indicate that AMPK down-regulates LECT2 expression in 
hepatocytes (Figure 5). 3) Glucose or insulin loading test revealed that Lect2 KO mice 
showed lower blood glucose levels after glucose or insulin injection. 4) 
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Hyperinsulinemic-euglycemic clamp studies showed that glucose infusion rate and 
peripheral glucose disposal were increased in Lect2 KO mice, whereas endogenous 
glucose production EGP was unaffected. These results indicate that Lect2 KO mice have 
better insulin sensitivity in skeletal muscle but not in the liver. 5) In vitro in C2C12 
myocytes, recombinant LECT2 protein phosphorylated JNK and decreased 
insulin-stimulated Akt phosphorylation, which was rescued by double knockdown of 
JNK1 and JNK2. 6) To further elucidate the role of LECT2 in the development of 
obesity-associated insulin resistance, we fed Lect2 KO mice a 60% HFD. Lect2 KO mice 
were protected from the HFD-induced weight gain. Serum levels of insulin decreased in 
the KO mice in both fasting and fed conditions. 7) Lect2 KO mice presented higher heat 
production in both light and dark phases. This may be caused by enhanced myogenesis, 
because all of the subsets of myosin heavy chain were up-regulated in the Lect2 KO mice. 
As a consequence, physical-exercise-assessed muscle endurance was significantly higher 
in Lect2 KO mice than wild-type mice. These findings suggest that LECT2 decreases 
energy expenditure by inhibiting myogenesis (Figure 5).  
In conclusion, LECT2 is a satiety-associated hepatokine that is induced by 
inactivating AMPK in the liver. Overproduction of LECT2 contributes to the 
development of muscle insulin resistance and obesity by activating JNK and by impairing 





1. Yamada T, Katagiri H. Avenues of communication between the brain 
and tissues/organs involved in energy homeostasis. Endocr J. 2007 Aug;54(4):497-505. 
PubMed PMID: 17510499. Epub 2007/05/19. eng. 
2. (OECD) TOfEC-oaD. OBESITY Update. 2014. 
3. (IDF) IDF. IDF DIABETES ATLAS 2014. 6:[Available from: 
http://www.idf.org/diabetesatlas. 
4. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. 
Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. 
Hepatology. 2007 Nov;46(5):1392-403. PubMed PMID: 17929294. eng. 
5. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, 
Noda H, et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through 
reactive oxygen species produced by mitochondria. The Journal of biological chemistry. 
2009 May 29;284(22):14809-18. PubMed PMID: 19332540. eng. 
6. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, 
Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are 
coordinately downregulated in human diabetes. Nat Genet. 2003 Jul;34(3):267-73. 
PubMed PMID: 12808457. 
7. Takamura T, Misu H, Matsuzawa-Nagata N, Sakurai M, Ota T, 
Shimizu A, et al. Obesity upregulates genes involved in oxidative phosphorylation in 
livers of diabetic patients. Obesity (Silver Spring). 2008 Dec;16(12):2601-9. PubMed 
PMID: 18846047. Epub 2008/10/11. eng. 
17 
 
8. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, 
Magnuson MA, et al. Loss of insulin signaling in hepatocytes leads to severe insulin 
resistance and progressive hepatic dysfunction. Mol Cell. 2000 Jul;6(1):87-97. PubMed 
PMID: 10949030. 
9. Lauro D, Kido Y, Castle AL, Zarnowski MJ, Hayashi H, Ebina Y, et al. 
Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle 
and adipose tissue. Nat Genet. 1998 Nov;20(3):294-8. PubMed PMID: 9806552. Epub 
1998/11/07. eng. 
10. Sakurai M, Takamura T, Ota T, Ando H, Akahori H, Kaji K, et al. Liver 
steatosis, but not fibrosis, is associated with insulin resistance in nonalcoholic fatty liver 
disease. J Gastroenterol. 2007 Apr;42(4):312-7. PubMed PMID: 17464461. eng. 
11. Kato K, Takamura T, Takeshita Y, Ryu Y, Misu H, Ota T, et al. Ectopic 
fat accumulation and distant organ-specific insulin resistance in Japanese people with 
nonalcoholic fatty liver disease. PLoS One. 2014;9(3):e92170. PubMed PMID: 
24651470. Pubmed Central PMCID: 3961287. 
12. Thamer C, Machann J, Bachmann O, Haap M, Dahl D, Wietek B, et al. 
Intramyocellular lipids: anthropometric determinants and relationships with maximal 
aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab. 2003 
Apr;88(4):1785-91. PubMed PMID: 12679474. 
13. Kim JK, Michael MD, Previs SF, Peroni OD, Mauvais-Jarvis F, 
Neschen S, et al. Redistribution of substrates to adipose tissue promotes obesity in mice 
with selective insulin resistance in muscle. J Clin Invest. 2000 Jun;105(12):1791-7. 
PubMed PMID: 10862794. Pubmed Central PMCID: 378504. 
18 
 
14. Flannery C, Dufour S, Rabol R, Shulman GI, Petersen KF. Skeletal 
muscle insulin resistance promotes increased hepatic de novo lipogenesis, 
hyperlipidemia, and hepatic steatosis in the elderly. Diabetes. 2012 Nov;61(11):2711-7. 
PubMed PMID: 22829450. Pubmed Central PMCID: 3478531. 
15. Uno K, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Imai J, et al. 
Neuronal pathway from the liver modulates energy expenditure and systemic insulin 
sensitivity. Science. 2006 Jun 16;312(5780):1656-9. PubMed PMID: 16778057. eng. 
16. Newgard CB. Interplay between lipids and branched-chain amino acids 
in development of insulin resistance. Cell Metab. 2012 May 2;15(5):606-14. PubMed 
PMID: 22560213. Pubmed Central PMCID: 3695706. 
17. Takamura T, Misu H, Ota T, Kaneko S. Fatty liver as a consequence 
and cause of insulin resistance: lessons from type 2 diabetic liver. Endocr J. 
2012;59(9):745-63. PubMed PMID: 22893453. 
18. Brown MS, Goldstein JL. Selective versus total insulin resistance: a 
pathogenic paradox. Cell Metab. 2008 Feb;7(2):95-6. PubMed PMID: 18249166. 
19. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, 
Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients 
with nonalcoholic fatty liver disease. J Clin Invest. 2005 May;115(5):1343-51. PubMed 
PMID: 15864352. Pubmed Central PMCID: 1087172. 
20. Rutkowski DT, Wu J, Back SH, Callaghan MU, Ferris SP, Iqbal J, et al. 
UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated 
suppression of transcriptional master regulators. Developmental cell. 2008 
Dec;15(6):829-40. PubMed PMID: 19081072. Pubmed Central PMCID: 2923556. 
19 
 
21. Shimano H. SREBP-1c and TFE3, energy transcription factors that 
regulate hepatic insulin signaling. Journal of molecular medicine. 2007 
May;85(5):437-44. PubMed PMID: 17279346. 
22. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. 
Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 
2004 Oct 15;306(5695):457-61. PubMed PMID: 15486293. 
23. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, 
et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse 
model of type 2 diabetes. Science. 2006 Aug 25;313(5790):1137-40. PubMed PMID: 
16931765. 
24. Walter P, Ron D. The unfolded protein response: from stress pathway 
to homeostatic regulation. Science. 2011 Nov 25;334(6059):1081-6. PubMed PMID: 
22116877. 
25. Yalcin A, Hotamisligil GS. Impact of ER protein homeostasis on 
metabolism. Diabetes. 2013 Mar;62(3):691-3. PubMed PMID: 23431011. Pubmed 
Central PMCID: 3581203. 
26. Voges D, Zwickl P, Baumeister W. The 26S proteasome: a molecular 
machine designed for controlled proteolysis. Annual review of biochemistry. 
1999;68:1015-68. PubMed PMID: 10872471. 
27. Otoda T, Takamura T, Misu H, Ota T, Murata S, Hayashi H, et al. 
Proteasome dysfunction mediates obesity-induced endoplasmic reticulum stress and 
insulin resistance in the liver. Diabetes. 2013 Mar;62(3):811-24. PubMed PMID: 
23209186. Pubmed Central PMCID: 3581221. 
20 
 
28. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic 
autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010 
Jun 9;11(6):467-78. PubMed PMID: 20519119. Pubmed Central PMCID: 2881480. 
29. Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of 
rapid degradation of nuclear sterol regulatory element-binding proteins by the 
ubiquitin-proteasome pathway. The Journal of biological chemistry. 2001 Sep 
28;276(39):36431-7. PubMed PMID: 11477106. 
30. Zhou Y, Lee J, Reno CM, Sun C, Park SW, Chung J, et al. Regulation 
of glucose homeostasis through a XBP-1-FoxO1 interaction. Nat Med. 2011 
Mar;17(3):356-65. PubMed PMID: 21317886. Pubmed Central PMCID: 3897616. 
31. Queisser MA, Yao D, Geisler S, Hammes HP, Lochnit G, Schleicher 
ED, et al. Hyperglycemia impairs proteasome function by methylglyoxal. Diabetes. 2010 
Mar;59(3):670-8. PubMed PMID: 20009088. Pubmed Central PMCID: 2828656. 
32. Portero-Otin M, Pamplona R, Ruiz MC, Cabiscol E, Prat J, Bellmunt 
MJ. Diabetes induces an impairment in the proteolytic activity against oxidized proteins 
and a heterogeneous effect in nonenzymatic protein modifications in the cytosol of rat 
liver and kidney. Diabetes. 1999 Nov;48(11):2215-20. PubMed PMID: 10535457. 
33. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates 
muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects 




34. Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. Endoplasmic 
reticulum stress plays a central role in development of leptin resistance. Cell Metab. 2009 
Jan 7;9(1):35-51. PubMed PMID: 19117545. 
35. Takamura T, Misu H, Yamashita T, Kaneko S. SAGE application in the 
study of diabetes. Curr Pharm Biotechnol. 2008 Oct;9(5):392-9. PubMed PMID: 
18855692. Epub 2008/10/16. eng. 
36. Misu H, Takamura T, Matsuzawa N, Shimizu A, Ota T, Sakurai M, et al. 
Genes involved in oxidative phosphorylation are coordinately upregulated with fasting 
hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia. 2007 
Feb;50(2):268-77. PubMed PMID: 17187250. 
37. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M, et al. 
Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. 
Gastroenterology. 2007 Jan;132(1):282-93. PubMed PMID: 17241878. eng. 
38. Matsuzawa-Nagata N, Takamura T, Ando H, Nakamura S, Kurita S, 
Misu H, et al. Increased oxidative stress precedes the onset of high-fat diet-induced 
insulin resistance and obesity. Metabolism. 2008 Aug;57(8):1071-7. PubMed PMID: 
18640384. eng. 
39. Ando H, Takamura T, Matsuzawa-Nagata N, Shima KR, Nakamura S, 
Kumazaki M, et al. The hepatic circadian clock is preserved in a lipid-induced mouse 
model of non-alcoholic steatohepatitis. Biochemical and biophysical research 




40. Misu H, Takamura T, Takayama H, Hayashi H, Matsuzawa-Nagata N, 
Kurita S, et al. A liver-derived secretory protein, selenoprotein P, causes insulin 
resistance. Cell Metab. 2010 Nov 3;12(5):483-95. PubMed PMID: 21035759. Epub 
2010/11/03. eng. 
41. Speckmann B, Walter PL, Alili L, Reinehr R, Sies H, Klotz LO, et al. 
Selenoprotein P expression is controlled through interaction of the coactivator 
PGC-1alpha with FoxO1a and hepatocyte nuclear factor 4alpha transcription factors. 
Hepatology. 2008 Dec;48(6):1998-2006. PubMed PMID: 18972406. 
42. Takayama H, Misu H, Iwama H, Chikamoto K, Saito Y, Murao K, et al. 
Metformin suppresses expression of the selenoprotein P gene via an AMP-activated 
kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes. The Journal of biological 
chemistry. 2014 Jan 3;289(1):335-45. PubMed PMID: 24257750. Pubmed Central 
PMCID: 3879556. 
43. Ishikura K, Misu H, Kumazaki M, Takayama H, Matsuzawa-Nagata N, 
Tajima N, et al. Selenoprotein P as a diabetes-associated hepatokine that impairs 
angiogenesis by inducing VEGF resistance in vascular endothelial cells. Diabetologia. 
2014 Sep;57(9):1968-76. PubMed PMID: 24989996. 
44. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, 
Combs GF, et al. Effects of long-term selenium supplementation on the incidence of type 
2 diabetes: a randomized trial. Ann Intern Med. 2007 Aug 21;147(4):217-23. PubMed 
PMID: 17620655. Epub 2007/07/11. eng. 
45. Iwakami S, Misu H, Takeda T, Sugimori M, Matsugo S, Kaneko S, et al. 
Concentration-dependent dual effects of hydrogen peroxide on insulin signal 
23 
 
transduction in H4IIEC hepatocytes. PLoS One. 2011;6(11):e27401. PubMed PMID: 
22102892. Pubmed Central PMCID: 3216925. Epub 2011/11/22. eng. 
46. Loh K, Deng H, Fukushima A, Cai X, Boivin B, Galic S, et al. Reactive 
oxygen species enhance insulin sensitivity. Cell Metab. 2009 Oct;10(4):260-72. PubMed 
PMID: 19808019. Epub 2009/10/08. eng. 
47. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M, Kiehntopf M, 
et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc 
Natl Acad Sci U S A. 2009 May 26;106(21):8665-70. PubMed PMID: 19433800. 
Pubmed Central PMCID: 2680430. Epub 2009/05/13. eng. 
48. Misu H, Ishikura K, Kurita S, Takeshita Y, Ota T, Saito Y, et al. Inverse 
correlation between serum levels of selenoprotein P and adiponectin in patients with type 
2 diabetes. PLoS One. 2012;7(4):e34952. PubMed PMID: 22496878. Pubmed Central 
PMCID: 3319626. Epub 2012/04/13. eng. 
49. Iwabu M, Yamauchi T, Okada-Iwabu M, Sato K, Nakagawa T, Funata 
M, et al. Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) 
and AMPK/SIRT1. Nature. 2010 Apr 29;464(7293):1313-9. PubMed PMID: 20357764. 
50. Lan F, Misu H, Chikamoto K, Takayama H, Kikuchi A, Mohri K, et al. 
LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance. 
Diabetes. 2014 May;63(5):1649-64. PubMed PMID: 24478397. 
51. Yamagoe S, Yamakawa Y, Matsuo Y, Minowada J, Mizuno S, Suzuki 
K. Purification and primary amino acid sequence of a novel neutrophil chemotactic factor 
LECT2. Immunology letters. 1996 Aug;52(1):9-13. PubMed PMID: 8877413. 
24 
 
52. Yamagoe S, Mizuno S, Suzuki K. Molecular cloning of human and 
bovine LECT2 having a neutrophil chemotactic activity and its specific expression in the 
liver. Biochimica et biophysica acta. 1998 Mar 4;1396(1):105-13. PubMed PMID: 
9524238. 
53. Lu XJ, Chen J, Yu CH, Shi YH, He YQ, Zhang RC, et al. LECT2 
protects mice against bacterial sepsis by activating macrophages via the CD209a receptor. 
The Journal of experimental medicine. 2013 Jan 14;210(1):5-13. PubMed PMID: 
23254286. Pubmed Central PMCID: 3549712. 
54. Chen CK, Yang CY, Hua KT, Ho MC, Johansson G, Jeng YM, et al. 
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress 
hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B 





Table 1.  Univariate correlation between ectopic fat and organ-specific insulin resistance 
HGP, hepatic glucose production; FPI, fasting plasma insulin; SSPI, steady state plasma 
insulin; IHL, intrahepatic lipid; IMCL, intramyocellular lipid; VO2, basal oxygen 
consumption rate per body weight. *p < 0.05, **p < 0.01, ***p < 0.001. (modified from 
Ref. (11)) 
 
Figure 1.  Relationship between intracellular lipid accumulation and origan-specific 
insulin resistance among 3 major insulin-targeting organs, the liver, skeletal muscle and 
adipose tissue.  
Skeletal muscle insulin resistance is not associated with intramyocellular lipid 
accumulation, but with hepatic steatosis, suggesting that there is inter-organ network 
between the liver and skeletal muscle in human. (modified from Ref. (11)) 
 
Figure 2.  Selective insulin resistance-like phenotype in the liver with type 2 diabetes.  
In the liver with type 2 diabetes, insulin fails to suppress gluconeogenesis but continues to 
activate lipogenesis, which is regarded as a ‘selective insulin resistance’-like phonetype.  
 
Figure 3.  Cross-talk among protein, glucose and lipid metabolic pathways.  
Proteasome function is impaired in the state of obesity, followed by endoplasmic 
reticulum (ER) stress, JNK activation and insulin resistance in the liver. Proteasome 
dysfunction also results in increased protein levels of FoxO1 and SREBP-1c because 
proteasome is responsible for degradation of FoxO1 and SREBP-1c, which are master 
26 
 
transcription factors for gluconeogenesis and lipogenesis, respectively. SREBP-1c is also 
activated by ER stress. Such activation of these factors occurs independently of insulin 
resistance, and may mimic so-called ‘selective insulin resistance’ in the liver with type 2 
diabetes, that is, coexistence of fatty liver and enhanced gluconeogenesis. (modified from 
Ref. (27)) 
 
Figure 4.  Selenoprotein P causes insulin resistance in the liver and skeletal muscle.  
SEPP1 is upregulated through FoxOs. Insulin downregulates SEPP1 by inactivating 
FoxO1, whereas antidiabetic metformin activates AMPK, inactivates FoxO3a, and 
thereby downregulates SEPP1 in hepatocytes. Selenoprotein P causes hepatic insulin 
resistance at least partly by inactivating AMPK. (modified from Ref. (48)) 
 
Figure 5.  A satiety-associated LECT2 causes skeletal muscle insulin resistance.  
LECT2 is a satiety-associated hepatokine that is induced by inactivating AMPK in the 
liver. Overproduction of LECT2 contributes to the development of muscle insulin 
resistance and obesity by activating JNK and by impairing myogenesis, respectively. 
(modified from Ref. (50)) 
 
    HGP×FPI   %HGP   Rd   Rd/SSPI   %FFA 
    r p   r p   r p   r p   r p 
Steatosis 0.401** 0.001 -0.161 0.187 -0.495*** <0.001 -0.460*** <0.001 -0.086 0.483 
Grade 0.397** 0.001 -0.151 0.214 -0.359** 0.002 -0.361** 0.003 -0.061 0.616 
Stage 0.227 0.060 -0.109 0.371 -0.300* 0.012 -0.248* 0.042 -0.001 0.991 
IHL 0.245 0.089 -0.114 0.436 -0.315* 0.028 -0.271 0.062 -0.135 0.356 
IMCL 0.250 0.065 -0.215 0.115 -0.156 0.256 -0.183 0.185 -0.060 0.662 
Fat-free 
mass 0.031 0.801 -0.117 0.347 -0.216 0.079 -0.211 0.090 -0.433*** <0.001 
Total fat 
mass 0.495*** <0.001 -0.147 0.235 -0.594*** <0.001 -0.536*** <0.001 -0.205 0.096 
Body fat 
percentage 0.481*** <0.001 -0.115 0.355 -0.518*** <0.001 -0.478*** <0.001 -0.001 0.994 
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